Cancers emerge from many different paths. One path begins early, in embryonic development, when a protein complex called PRC2 ...

This biological process, where mature, specialized cells lose their distinct characteristics and revert to a more primitive, aggressive state, is a universally recognized sign of poor prognosis across ...

Great Novel Therapeutics Biotech & Medicals Corporation (GNTbm) (stock code: 7427) announced that its independently developed novel epigenetic immunoactivator GNTbm-38, with global rights for cancer ...

VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, is the first to demonstrate the isolation and analysis of >99% pure circulating tumor-derived DNA (ctDNA).

Researchers discovered that a small region of the PRC2 protein complex acts as a functional switch controlling gene silencing. Removing this domain stopped cancer cell growth, highlighting a potential ...

Chromatin is one of the earliest identified targets for cancer therapeutics. Drug development aimed at altering chromatin can be traced to the differentiating agents of the 1970s and their link to DNA ...

The role of epigenetic mechanisms in cancer has gained interest in recent studies. The reversible nature of epigenetic changes on genomic DNA and histones holds promise for the development of ...

Advances in understanding the epigenetic landscape of CRC have spurred interest in epigenetic modifiers, or "epidrugs," which offer a novel approach by targeting the reversible nature of epigenetic ...

Methylation and cancer While these papers looked at the role of chromatin in the genetic expression of cancers, there are other laboratories looking at the role of methylation, another epigenetic ...

A little-known mouse protein disrupts cancer-causing chemical changes to genes associated with human colorectal cancer cells and potentially could be used to treat solid tumors, according to a new ...